Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma

Trial Profile

Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Astrocytoma; Glioma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 May 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2017, as reported by ClinicalTrials.gov record (NCT00831324).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top